Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles

Benjamin B. Kasten; Tiancheng Liu; Jessie R. Nedrow-Byers; Paul D. Benny; Clifford E. Berkman

doi:10.1016/j.bmcl.2012.11.015

Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles

Benjamin B. Kasten, Tiancheng Liu, Jessie R. Nedrow-Byers, Paul D. Benny, Clifford E. Berkman

Research output: Contribution to journal › Article › peer-review

Abstract

Prostate-specific membrane antigen (PSMA) is a notable biomarker for diagnostic and therapeutic applications in prostate cancer. Gold nanoparticles (AuNPs) provide an attractive nanomaterial platform for combining a variety of targeting, imaging, and cytotoxic agents into a unified device for biomedical research. In this study, we present the generation and evaluation of the first AuNP system functionalized with a small molecule phosphoramidate peptidomimetic inhibitor for the targeted delivery to PSMA-expressing prostate cancer cells. The general approach involved the conjugation of streptavidin-coated AuNPs with a biotin-linked PSMA inhibitor (CTT54) to generate PSMA-targeted AuNPs. In vitro evaluations of these targeted AuNPs were conducted to determine PSMA-mediated and time-dependent binding to PSMA-positive LNCaP cells. The PSMA-targeted AuNPs exhibited significantly higher and selective binding to LNCaP cells compared to control non-targeted AuNPs, thus demonstrating the feasibility of this approach.

Original language	English (US)
Pages (from-to)	565-568
Number of pages	4
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	23
Issue number	2
DOIs	https://doi.org/10.1016/j.bmcl.2012.11.015
State	Published - Jan 15 2013
Externally published	Yes

Keywords

Biotin
Gold nanoparticles
Prostate cancer
Prostate-specific membrane antigen
Streptavidin

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Molecular Biology
Pharmaceutical Science
Drug Discovery
Clinical Biochemistry
Organic Chemistry

Access to Document

10.1016/j.bmcl.2012.11.015

Cite this

@article{d11287a456d9417d99e3371785125448,

title = "Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles",

abstract = "Prostate-specific membrane antigen (PSMA) is a notable biomarker for diagnostic and therapeutic applications in prostate cancer. Gold nanoparticles (AuNPs) provide an attractive nanomaterial platform for combining a variety of targeting, imaging, and cytotoxic agents into a unified device for biomedical research. In this study, we present the generation and evaluation of the first AuNP system functionalized with a small molecule phosphoramidate peptidomimetic inhibitor for the targeted delivery to PSMA-expressing prostate cancer cells. The general approach involved the conjugation of streptavidin-coated AuNPs with a biotin-linked PSMA inhibitor (CTT54) to generate PSMA-targeted AuNPs. In vitro evaluations of these targeted AuNPs were conducted to determine PSMA-mediated and time-dependent binding to PSMA-positive LNCaP cells. The PSMA-targeted AuNPs exhibited significantly higher and selective binding to LNCaP cells compared to control non-targeted AuNPs, thus demonstrating the feasibility of this approach.",

keywords = "Biotin, Gold nanoparticles, Prostate cancer, Prostate-specific membrane antigen, Streptavidin",

author = "Kasten, {Benjamin B.} and Tiancheng Liu and Nedrow-Byers, {Jessie R.} and Benny, {Paul D.} and Berkman, {Clifford E.}",

note = "Funding Information: The authors extend their gratitude for technical assistance with ICP-OES to J. Lessmann, as well as C. Davitt and V. Lynch-Holm at the WSU Franceschi Microscopy and Imaging Center. This work was supported by the National Institutes of Health ( 5R01CA140617 and T32GM008336 ). ",

year = "2013",

month = jan,

day = "15",

doi = "10.1016/j.bmcl.2012.11.015",

language = "English (US)",

volume = "23",

pages = "565--568",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles

AU - Kasten, Benjamin B.

AU - Liu, Tiancheng

AU - Nedrow-Byers, Jessie R.

AU - Benny, Paul D.

AU - Berkman, Clifford E.

N1 - Funding Information: The authors extend their gratitude for technical assistance with ICP-OES to J. Lessmann, as well as C. Davitt and V. Lynch-Holm at the WSU Franceschi Microscopy and Imaging Center. This work was supported by the National Institutes of Health ( 5R01CA140617 and T32GM008336 ).

PY - 2013/1/15

Y1 - 2013/1/15

N2 - Prostate-specific membrane antigen (PSMA) is a notable biomarker for diagnostic and therapeutic applications in prostate cancer. Gold nanoparticles (AuNPs) provide an attractive nanomaterial platform for combining a variety of targeting, imaging, and cytotoxic agents into a unified device for biomedical research. In this study, we present the generation and evaluation of the first AuNP system functionalized with a small molecule phosphoramidate peptidomimetic inhibitor for the targeted delivery to PSMA-expressing prostate cancer cells. The general approach involved the conjugation of streptavidin-coated AuNPs with a biotin-linked PSMA inhibitor (CTT54) to generate PSMA-targeted AuNPs. In vitro evaluations of these targeted AuNPs were conducted to determine PSMA-mediated and time-dependent binding to PSMA-positive LNCaP cells. The PSMA-targeted AuNPs exhibited significantly higher and selective binding to LNCaP cells compared to control non-targeted AuNPs, thus demonstrating the feasibility of this approach.

AB - Prostate-specific membrane antigen (PSMA) is a notable biomarker for diagnostic and therapeutic applications in prostate cancer. Gold nanoparticles (AuNPs) provide an attractive nanomaterial platform for combining a variety of targeting, imaging, and cytotoxic agents into a unified device for biomedical research. In this study, we present the generation and evaluation of the first AuNP system functionalized with a small molecule phosphoramidate peptidomimetic inhibitor for the targeted delivery to PSMA-expressing prostate cancer cells. The general approach involved the conjugation of streptavidin-coated AuNPs with a biotin-linked PSMA inhibitor (CTT54) to generate PSMA-targeted AuNPs. In vitro evaluations of these targeted AuNPs were conducted to determine PSMA-mediated and time-dependent binding to PSMA-positive LNCaP cells. The PSMA-targeted AuNPs exhibited significantly higher and selective binding to LNCaP cells compared to control non-targeted AuNPs, thus demonstrating the feasibility of this approach.

KW - Biotin

KW - Gold nanoparticles

KW - Prostate cancer

KW - Prostate-specific membrane antigen

KW - Streptavidin

UR - http://www.scopus.com/inward/record.url?scp=84871714149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871714149&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2012.11.015

DO - 10.1016/j.bmcl.2012.11.015

M3 - Article

C2 - 23232055

AN - SCOPUS:84871714149

VL - 23

SP - 565

EP - 568

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 2

ER -

Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this